Table 1.
Characteristics of study
| Fluoroquinolones | Total | With | Without | P | |||
|---|---|---|---|---|---|---|---|
| Variables | n | % | n | % | n | % | |
| Total | 167,105 | 33,421 | 20.00 | 133,684 | 80.00 | ||
| Collagen-associated adverse events | 0.990 | ||||||
| Without | 167,020 | 99.95 | 33,404 | 99.95 | 133,616 | 99.95 | |
| With | 85 | 0.05 | 17 | 0.05 | 68 | 0.05 | |
| Collagen-associated adverse events subgroups | 0.990 | ||||||
| Without | 167,020 | 99.95 | 33,404 | 99.95 | 133,616 | 99.95 | |
| Tendons rupture | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| Retinal detachments | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| Gastrointestinal perforation | 85 | 0.05 | 17 | 0.05 | 68 | 0.05 | |
| Aortic dissection/Aortic aneurysm | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
| Gender | 0.999 | ||||||
| Male | 85,990 | 51.46 | 17,198 | 51.46 | 68,792 | 51.46 | |
| Female | 81,115 | 48.54 | 16,223 | 48.54 | 64,892 | 48.54 | |
| Age (years) | 9.78 ± 5.58 | 9.83 ± 5.35 | 9.77 ± 5.63 | 0.079 | |||
| Age group (years) | 0.999 | ||||||
| < 1 | 5100 | 3.05 | 1020 | 3.05 | 4080 | 3.05 | |
| 1 | 7145 | 4.28 | 1429 | 4.28 | 5716 | 4.28 | |
| 2 | 7970 | 4.77 | 1594 | 4.77 | 6376 | 4.77 | |
| 3 | 9060 | 5.42 | 1812 | 5.42 | 7248 | 5.42 | |
| 4 | 10,680 | 6.39 | 2136 | 6.39 | 8544 | 6.39 | |
| 5–9 | 46,670 | 27.93 | 9334 | 27.93 | 37,336 | 27.93 | |
| 10–14 | 42,785 | 25.60 | 8557 | 25.60 | 34,228 | 25.60 | |
| ≧15 | 37,695 | 22.56 | 7539 | 22.56 | 30,156 | 22.56 | |
| Catastrophic illness | < 0.001 | ||||||
| Without | 166,398 | 99.58 | 33,222 | 99.40 | 133,176 | 99.62 | |
| With | 707 | 0.42 | 199 | 0.60 | 508 | 0.38 | |
| Low-income household | < 0.001 | ||||||
| Without | 164,089 | 98.20 | 32,561 | 97.43 | 131,528 | 98.39 | |
| With | 3016 | 1.80 | 860 | 2.57 | 2156 | 1.61 | |
| Season | < 0.001 | ||||||
| Spring (Mar - May) | 43,867 | 26.25 | 8757 | 26.20 | 35,110 | 26.26 | |
| Summer (Jun - Aug) | 42,836 | 25.63 | 8435 | 25.24 | 34,401 | 25.73 | |
| Autumn (Sep - Nov) | 41,287 | 24.71 | 8289 | 24.80 | 32,998 | 24.68 | |
| Winter (Dec - Feb) | 39,115 | 23.41 | 7940 | 23.76 | 31,175 | 23.32 | |
| Urbanization level | < 0.001 | ||||||
| 1 (the highest) | 45,240 | 27.07 | 7343 | 21.97 | 37,897 | 28.35 | |
| 2 | 62,222 | 37.24 | 11,929 | 35.69 | 50,293 | 37.62 | |
| 3 | 27,980 | 16.74 | 6433 | 19.25 | 21,547 | 16.12 | |
| 4 (the lowest) | 31,663 | 18.95 | 7716 | 23.09 | 23,947 | 17.91 | |
| Level of care | < 0.001 | ||||||
| Hospital center | 7559 | 4.52 | 1268 | 3.79 | 6291 | 4.71 | |
| Regional hospital | 11,858 | 7.10 | 1939 | 5.80 | 9919 | 7.42 | |
| Local hospital | 8762 | 5.49 | 1588 | 4.94 | 7174 | 5.63 | |
| Physician clinics | 138,926 | 83.14 | 28,626 | 85.65 | 110,300 | 82.51 | |
| Comorbidities | |||||||
| Cerebrovascular accident | 43 | 0.03 | 8 | 0.02 | 35 | 0.03 | 0.819 |
| Diabetes mellitus | 84 | 0.05 | 18 | 0.05 | 66 | 0.05 | 0.743 |
| Hypertension | 96 | 0.06 | 20 | 0.06 | 76 | 0.06 | 0.838 |
| Hyperlipidemia | 74 | 0.04 | 15 | 0.04 | 59 | 0.04 | 0.954 |
| Drugs | |||||||
| Non-steroidal anti-inflammatory drugs | 5008 | 3.00 | 1023 | 3.06 | 3985 | 2.98 | 0.443 |
| Systemic steroid | 915 | 0.55 | 188 | 0.56 | 727 | 0.54 | 0.679 |
P: Chi-square / Fisher exact test on category variables and t-test on continue variables